Published in NPJ Syst Biol Appl on September 20, 2017
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol (2005) 5.68
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
A large-scale evaluation of computational protein function prediction. Nat Methods (2013) 4.61
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol (2011) 3.52
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist (2002) 2.62
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal (2009) 2.57
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett (2001) 2.15
A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol (2014) 2.12
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Crosstalk in Met receptor oncogenesis. Trends Cell Biol (2009) 1.70
Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.70
2014 FDA drug approvals. Nat Rev Drug Discov (2015) 1.62
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal (2015) 1.58
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One (2013) 1.50
State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods (2006) 1.50
What are decision trees? Nat Biotechnol (2008) 1.39
Chemoresistance in solid tumours. Ann Oncol (2006) 1.39
Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res (1990) 1.33
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
Translational research: 4 ways to fix the clinical trial. Nature (2011) 1.20
Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal (2013) 1.17
Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems. Bioinformatics (2015) 1.08
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal (2013) 1.07
Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer (2000) 1.06
Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling. Mol Cell Proteomics (2011) 1.05
Inferring causal molecular networks: empirical assessment through a community-based effort. Nat Methods (2016) 1.04
mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res (2009) 1.00
Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol Syst Biol (2016) 0.99
Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. J Biol Chem (2014) 0.93
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol Cancer Ther (2015) 0.92
Quantifying protein-protein interactions in high throughput using protein domain microarrays. Nat Protoc (2010) 0.91
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther (2013) 0.91
Dormancy of cancer cells with suppression of AKT activity contributes to survival in chronic hypoxia. PLoS One (2014) 0.85
The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet (2016) 0.81
Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer (2016) 0.80
A data-driven computational model of the ErbB receptor signaling network. Conf Proc IEEE Eng Med Biol Soc (2006) 0.79
Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells. Mol Cancer Ther (2015) 0.76
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ Syst Biol Appl (2017) 0.76
Predicting cancer drug response: advancing the DREAM. Cancer Discov (2015) 0.76
Customized Steady-State Constraints for Parameter Estimation in Non-Linear Ordinary Differential Equation Models. Front Cell Dev Biol (2016) 0.76
Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer (2016) 0.76
Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC. Transl Lung Cancer Res (2014) 0.76
Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway. Sci Signal (2016) 0.76
Driving the Model to Its Limit: Profile Likelihood Based Model Reduction. PLoS One (2016) 0.75